Revolution Medicines director sells 17,090 shares

A Revolution Medicines director’s revocable trust executed pre-planned open-market sales totaling 17,090 RVMD shares, while the director retains 1,191 restricted stock units.

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) director Lorence H. Kim reported indirect sales of common stock held by the Lorence Kim Revocable Trust. On September 8, 2026, the trust sold 17,090 shares of RVMD common stock in multiple open-market transactions at weighted-average prices within specified ranges, pursuant to a Rule 10b5-1 trading plan adopted on June 1, 2026. Separately, Kim continues to hold 1,191 restricted stock units directly.

Insider Trade Summary 10b5-1

Net Seller: 17,090 shares

Net Sell 8 txns

Insider Kim Lorence H.

Role Director

Sold 17,090 shs ($3.59M)

Type	Security	Shares	Price	Value
Sale	Common Stock F2, F3, F4	706	$206.6049	$146K
Sale	Common Stock F2, F5, F4	999	$207.3321	$207K
Sale	Common Stock F2, F6, F4	3,587	$208.5534	$748K
Sale	Common Stock F2, F7, F4	2,853	$209.56	$598K
Sale	Common Stock F2, F8, F4	4,730	$210.5028	$996K
Sale	Common Stock F2, F9, F4	3,844	$211.3588	$812K
Sale	Common Stock F2, F10, F4	371	$212.2693	$79K
holding	Common Stock F1	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Indirect, Trust); Common Stock — 1,191 shares (Direct)

Footnotes (10)

1. F1. Includes 1,191 restricted stock units.
2. F2. Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026.
3. F3. The transaction was executed in multiple trades at prices ranging from $206.47 to $206.9903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
4. F4. Shares held by the Lorence Kim Revocable Trust.
5. F5. The transaction was executed in multiple trades at prices ranging from $207.02 to $207.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
6. F6. The transaction was executed in multiple trades at prices ranging from $208.05 to $208.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
7. F7. The transaction was executed in multiple trades at prices ranging from $209.08 to $209.9809, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
8. F8. The transaction was executed in multiple trades at prices ranging from $210.0114 to $210.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
9. F9. The transaction was executed in multiple trades at prices ranging from $211.00 to $211.9425, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
10. F10. The transaction was executed in multiple trades at prices ranging from $212.0775 to $212.3903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Total shares sold: 17,090 shares Sale price range: $206.47–$212.3903 per share Example weighted average sale price: $210.5028 per share +3 more

6 metrics

Total shares sold 17,090 shares Common stock sold indirectly by the Lorence Kim Revocable Trust on September 8, 2026

Sale price range $206.47–$212.3903 per share Price ranges across the multiple trades executed on September 8, 2026

Example weighted average sale price $210.5028 per share Weighted average price for a 4,730-share sale lot on September 8, 2026

Direct restricted stock units 1,191 units RSUs held directly by Lorence H. Kim after the reported transactions

Number of sale transactions 7 transactions Open-market or private sale transactions reported for September 8, 2026

10b5-1 plan adoption date June 1, 2026 Adoption date of the Lorence Kim Revocable Trust’s Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, restricted stock units, weighted average sale price, Revocable Trust

4 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"Includes 1,191 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported in Column 4 above reflects the weighted average sale price"

Revocable Trust financial

"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RVMD director Lorence H. Kim report?

Lorence H. Kim reported that the Lorence Kim Revocable Trust sold 17,090 shares of Revolution Medicines common stock on September 8, 2026 in a series of open-market transactions at weighted-average prices within specified ranges.

At what prices were the 17,090 RVMD shares sold by the trust?

The disclosed sales by the Lorence Kim Revocable Trust on September 8, 2026 occurred in multiple trades at prices ranging from approximately $206.47 to $212.3903 per share, with each reported price representing a weighted average sale price for that transaction.

Were the RVMD insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026, and the Rule 10b5-1 checkbox for the filing is affirmed.

How many RVMD shares does Lorence H. Kim hold directly after these transactions?

The filing reports that Lorence H. Kim holds 1,191 restricted stock units directly. These RSUs are separate from the shares sold by the Lorence Kim Revocable Trust, which are held indirectly through the trust.

Are the RVMD shares sold owned directly by Lorence H. Kim?

No. The shares sold are held by the Lorence Kim Revocable Trust and reported as indirect ownership. A footnote clarifies that the shares are held by this trust, distinguishing them from Kim’s directly held restricted stock units.

How many separate sale transactions of RVMD stock were reported for September 8, 2026?

The Form 4 reports seven separate open-market sale transactions of Revolution Medicines common stock on September 8, 2026, all attributed to the Lorence Kim Revocable Trust and summarized as total sales of 17,090 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 05:53 PM EDT Accepted by SEC EDGAR 09/10/2026 - 05:52 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Lorence H.

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								1,191(1)	D
Common Stock	09/08/2026		S(2)		706	D	$206.6049(3)	16,384	I	Trust(4)
Common Stock	09/08/2026		S(2)		999	D	$207.3321(5)	15,385	I	Trust(4)
Common Stock	09/08/2026		S(2)		3,587	D	$208.5534(6)	11,798	I	Trust(4)
Common Stock	09/08/2026		S(2)		2,853	D	$209.56(7)	8,945	I	Trust(4)
Common Stock	09/08/2026		S(2)		4,730	D	$210.5028(8)	4,215	I	Trust(4)
Common Stock	09/08/2026		S(2)		3,844	D	$211.3588(9)	371	I	Trust(4)
Common Stock	09/08/2026		S(2)		371	D	$212.2693(10)	0	I	Trust(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 1,191 restricted stock units.

2. Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026.

3. The transaction was executed in multiple trades at prices ranging from $206.47 to $206.9903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. Shares held by the Lorence Kim Revocable Trust.

5. The transaction was executed in multiple trades at prices ranging from $207.02 to $207.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

6. The transaction was executed in multiple trades at prices ranging from $208.05 to $208.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

7. The transaction was executed in multiple trades at prices ranging from $209.08 to $209.9809, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

8. The transaction was executed in multiple trades at prices ranging from $210.0114 to $210.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

9. The transaction was executed in multiple trades at prices ranging from $211.00 to $211.9425, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

10. The transaction was executed in multiple trades at prices ranging from $212.0775 to $212.3903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

	/s/ Jack Anders, as Attorney-in-fact for Lorence H. Kim	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)